ATE469641T1 - Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren - Google Patents

Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren

Info

Publication number
ATE469641T1
ATE469641T1 AT05802903T AT05802903T ATE469641T1 AT E469641 T1 ATE469641 T1 AT E469641T1 AT 05802903 T AT05802903 T AT 05802903T AT 05802903 T AT05802903 T AT 05802903T AT E469641 T1 ATE469641 T1 AT E469641T1
Authority
AT
Austria
Prior art keywords
fatty acids
alkyl esters
polyunsaturated fatty
pharmaceutical formulation
statin
Prior art date
Application number
AT05802903T
Other languages
English (en)
Inventor
Paolo Carminati
Antonio Parente
Original Assignee
Gp Pharm Sa
Defiante Farmaceutica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp Pharm Sa, Defiante Farmaceutica Sa filed Critical Gp Pharm Sa
Application granted granted Critical
Publication of ATE469641T1 publication Critical patent/ATE469641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05802903T 2004-10-19 2005-10-13 Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren ATE469641T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200402492A ES2255426B1 (es) 2004-10-19 2004-10-19 Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
PCT/ES2005/000542 WO2006045865A1 (es) 2004-10-19 2005-10-13 Formulación farmacéutica que comprende microcapsulas de estatinas suspendidas en ester alquílicos de ácidos grasos poliinsaturados (pufa)

Publications (1)

Publication Number Publication Date
ATE469641T1 true ATE469641T1 (de) 2010-06-15

Family

ID=36227494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05802903T ATE469641T1 (de) 2004-10-19 2005-10-13 Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren

Country Status (22)

Country Link
US (1) US20090196920A1 (de)
EP (1) EP1803440B1 (de)
JP (1) JP4976302B2 (de)
KR (1) KR101413339B1 (de)
CN (2) CN102727462A (de)
AT (1) ATE469641T1 (de)
AU (1) AU2005298587B2 (de)
BR (1) BRPI0516152A (de)
CA (1) CA2583756C (de)
CY (1) CY1110751T1 (de)
DE (1) DE602005021668D1 (de)
DK (1) DK1803440T3 (de)
EA (1) EA012371B1 (de)
ES (2) ES2255426B1 (de)
IL (1) IL182466A (de)
MX (1) MX2007004655A (de)
NZ (1) NZ554265A (de)
PL (1) PL1803440T3 (de)
PT (1) PT1803440E (de)
SI (1) SI1803440T1 (de)
WO (1) WO2006045865A1 (de)
ZA (1) ZA200703509B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
PT2018153E (pt) * 2006-04-26 2012-07-04 Rosemont Pharmaceuticals Ltd Composições orais líquidas
JP2009541433A (ja) * 2006-06-26 2009-11-26 ヴァルファルマ ソチエタ アノニマ オメガポリエン脂肪酸の経口投与のための医薬品の組成物、及び１又はそれ以上の配合禁忌の有効成分、並びにその調剤の工程
CN101484144A (zh) * 2006-07-06 2009-07-15 特瓦特药工业有限公司 具有受控药物动力学的组合物
ITMI20072142A1 (it) 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP2229939A4 (de) * 2008-01-10 2011-04-27 Takeda Pharmaceutical Kapselformulierung
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3318255B1 (de) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur behandlung des schlaganfalles bei patienten mit gleichzeitiger statin-therapie
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es) * 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
KR20120104270A (ko) * 2009-12-23 2012-09-20 데피안떼 파마슈띠까 에스.에이. 심혈관계 질환 치료에 유용한 복합 조성물
CA2706272C (en) 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
JP5829607B2 (ja) 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
HK1206248A1 (en) * 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
RU2600804C2 (ru) 2012-05-22 2016-10-27 Кухниль Фарм. Ко., Лтд. Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014182003A1 (en) * 2013-05-06 2014-11-13 Hanmi Pharm. Co., Ltd. Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
RU2614734C2 (ru) * 2015-05-21 2017-03-28 Татьяна Алексеевна Денисюк Способ получения нанокапсул розувастатина в каррагинане
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
WO2019143981A1 (en) * 2018-01-19 2019-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
WO2022129002A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Coarse dispersion comprising statin and vitamin e oil
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (de) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
HK1044704A1 (zh) 1999-03-31 2002-11-01 Abbott Laboratories 含有脂调节剂的新配方
MXPA01009840A (es) 1999-03-31 2002-06-21 Abbott Lab Nuevas formulaciones que comprenden agentes reguladores de lipido.
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
WO2002043659A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
CA2450238A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
CA2520660C (en) * 2003-03-28 2013-08-20 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules

Also Published As

Publication number Publication date
AU2005298587A1 (en) 2006-05-04
ES2255426A1 (es) 2006-06-16
US20090196920A1 (en) 2009-08-06
JP2008517040A (ja) 2008-05-22
DE602005021668D1 (de) 2010-07-15
PT1803440E (pt) 2010-08-31
EP1803440B1 (de) 2010-06-02
DK1803440T3 (da) 2010-10-04
ES2347055T3 (es) 2010-10-25
NZ554265A (en) 2010-12-24
IL182466A0 (en) 2007-07-24
AU2005298587B2 (en) 2010-08-05
IL182466A (en) 2013-06-27
MX2007004655A (es) 2008-03-10
KR20070083715A (ko) 2007-08-24
EA200700614A1 (ru) 2007-10-26
ZA200703509B (en) 2008-09-25
JP4976302B2 (ja) 2012-07-18
CY1110751T1 (el) 2015-06-10
PL1803440T3 (pl) 2010-12-31
SI1803440T1 (sl) 2010-10-29
EA012371B1 (ru) 2009-10-30
CA2583756A1 (en) 2006-05-04
CA2583756C (en) 2013-12-24
ES2255426B1 (es) 2007-08-16
BRPI0516152A (pt) 2008-08-26
CN101043873A (zh) 2007-09-26
EP1803440A1 (de) 2007-07-04
WO2006045865A1 (es) 2006-05-04
CN102727462A (zh) 2012-10-17
KR101413339B1 (ko) 2014-06-27

Similar Documents

Publication Publication Date Title
ATE469641T1 (de) Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren
AR051421A1 (es) Composiciones de aceites ricos en acidos grasos poliinsaturados (pufa)
SI1773312T1 (sl) Sestavek, ki vsebuje statine in maščobne kisline omega-3
ATE457720T2 (de) Weichgelatinekapsel mit mehrfach ungesättigten omega-3-fettsäuren
DK2436275T3 (da) Lipidsammensætning til forbedring af hjernefunktion
EE05320B1 (et) Eikosapentaeenhappe etlestri ja dokosaheksaeenhappe etlestri segu sisaldava essentsiaalse rasvhappe kasutamine
AR042332A1 (es) Composiciones de gliceridos y metodos de elaboracion y uso de las mismas
FR2955459B1 (fr) Composition huileuse riche en monoglycerides de dha
ATE331510T1 (de) Verwendung von polyungesättigten fettsäuren zur primären vorbeugung von kardiovaskulären anfällen
EE200300599A (et) Koensüüm Q ja EPA või muu asendamatu rasvhape
IL183246A0 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
ATE422350T1 (de) Anisinsäure und glyceride enthaltende zusammensetzungen
BRPI0705244A (pt) composição oleosa de ácido linolênico conjugado
DE602004017705D1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
AU2003217759A8 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
CO5700769A2 (es) Composicion farmaceutica de liberacion prolongada
ATE356622T1 (de) Einen lipase-inhibitor und einen saccharosefettsäuremonoester enthaltende pharmazeutische zusammensetzung
ATE390138T1 (de) Dipyridamol enthaltende zusammensetzungen mit verlängerter freisetzung und verfahren zu deren herstellung
ATE439362T1 (de) Ester in position 20 von camptothecinen
ITMI20022511A1 (it) Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
AR056268A1 (es) Tabletas que comprenden una sustancia biologicamente activa y un excipiente
ATE228556T1 (de) An omega-3 ungesättigten fettsäuren angereicherte wachsester, ihre herstellung und verwendung
AR053005A1 (es) Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa)
ATE502097T1 (de) Pharmazeutische zubereitungen, die fettsäureester von l-ascorbinsäure enthalten
NO20022578D0 (no) Fosfolipider inneholdende omega-3 fettsyrer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1803440

Country of ref document: EP